-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATI-2138 in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATI-2138 in Ulcerative Colitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATI-2138 in Ulcerative Colitis Drug Details: ATI-2138 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMG-305 in Head And Neck Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMG-305 in Head And Neck Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMG-305 in Head And Neck Cancer Drug Details: Monoclonal...
-
Product Insights
NewBorderline Personality Disorder (BPD) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Borderline Personality Disorder (BPD) Clinical Trial Report Overview A total of 71 borderline personality disorder (BPD) clinical trials were conducted as of March 2024. The borderline personality disorder (BPD) clinical trial report provides a comprehensive understanding of the borderline personality disorder (BPD) clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with...
-
Product Insights
Sensory Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Sensory Disorders - Drugs In Development, 2023’, provides an overview of the Sensory Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sensory Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Hyperalgesia – Drugs In Development, 2023
Global Markets Direct’s, ‘Hyperalgesia - Drugs In Development, 2023’, provides an overview of the Hyperalgesia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hyperalgesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Cognitive Impairment – Drugs In Development, 2023
Global Markets Direct’s, ‘Cognitive Impairment - Drugs In Development, 2023’, provides an overview of the Cognitive Impairment pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
High-Grade Glioma – Drugs In Development, 2023
Global Markets Direct’s, ‘High-Grade Glioma - Drugs In Development, 2023’, provides an overview of the High-Grade Glioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for High-Grade Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EP-262 in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EP-262 in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EP-262 in Atopic Dermatitis (Atopic Eczema) Drug Details: EP-262 is...
-
Product Insights
Shangrao Top Runner Solar PV Park
Shangrao Top Runner Solar PV Park is a solar PV project located in Jiangxi, China. The project is owned by Northwest Institute of China Energy Construction Planning and Design Group and is developed by Northwest Institute of China Energy Construction Planning and Design Group; Poyang Luohong Power Co Ltd. The project is at the permitting stage. Empower your strategies with our Shangrao Top Runner Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report...